WASHINGTON, D.C. – Andrew Fish, executive director of AdvaMedDx, and chief strategy officer of AdvaMed, today issued the following statement regarding release of a discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA) in the U.S. House of Representatives: Read more.
AdvaMedDx recently announced a global stakeholder initiative to optimize the use of diagnostic tests in the fight against antimicrobial resistance (AMR). Read more.
February 23, 2017 - 2:10pm
February 21, 2017 - 12:25pm